Prescribing of anti-osteoporotic therapies following the use of Proton Pump Inhibitors in general practice
|
|
- Shonda Stewart
- 5 years ago
- Views:
Transcription
1 Prescribing of anti-osteoporotic therapies following the use of Proton Pump Inhibitors in general practice B. McGowan, K. Bennett, J. Feely Department of Pharmacology & Therapeutics, Trinity Centre for Health Sciences, St James s Hospital, Dublin
2 Background Approximately 11% of the Irish population are over the age of 65 (468,000).By 2031 this proportion will increase to 18% i.e to over 1 million older people. International literature suggests that 1/3 of women and 1/5 of men over 50yrs suffer from osteoporosis. If we apply these rates in Ireland to the age grp 65 and over, it is estimated that approx. 84,567 women and 39,420 men have osteoporosis (N=123,987). Osteoporosis is a skeletal disease characterised by low bone density with a resulting increase in bone fragility and therefore increased risk of fracture. In women, the one in six lifetime risk of hip fracture is greater than the one in nine risk of developing breast cancer.
3 Osteoporosis Fractures of the hip, vertebral body, pelvis and distal forearm have generally been considered as the typical osteoporotic fractures. Of all fractures hip fractures can often have the most devastating consequences on patients. The mortality rate within the first twelve months following the fracture can be as high as 20%. Among patients who survive the trauma of the fracture, 1 in 5 will be admitted to a nursing home.
4 Osteoporosis (cont d) Approx 130,000 individuals aged 65 and over fall each year > of these about 108,000 do not seek medical attention, > about 1,500 are admitted to hospital for other injuries due to falls > almost 7,000 are admitted to hospital for fractures, utilising 5.2% of the 1.8 million hospital bed days used by older people. Mean length of hospital stay for colles fracture is 4.2 days and for hip fracture 17.1 days. The results of the Irish Burden of Illness Study shows that in financial terms fall related injuries in older people cost 402 million to the economy. Ref: Strategy to Prevent Falls and Fractures in Ireland s Ageing Population by the National Council on Ageing and Older People Jan 2008
5 Oral Bisphosphates Oral bisphosphonates represent a significant advance in the management of osteoporosis in the past ten years, with results of clinical trials demonstrating reductions in : - the risk of vertebral fractures as high as 40-50% - and in non-vertebral fractures between 20-40%. They are considered first line therapy for the prevention of osteoporosis in postmenopausal women and the prevention and treatment of corticosteroid-induced osteoporosis (CIO). Antiresorptive agents increase BMD and decrease fracture risk by reducing bone turnover and restoring the balance between bone resorption and bone formation
6 The effects of different therapeutic agents on bone mineral density (BMD). A number of studies have identified that certain drug groups may have a beneficial effect on bone mineral density subsequently reducing the risk of hip fractures such as : > statins, > thiazides, > beta blockers > Ca Channel Blockers > Angiotension 11 rec antagonists and > Ace Inhibitors. In contrast an increasing number of studies are showing that drug groups such as: > corticosteroids,> antiepileptic drugs, >antidepressants (Selective Serotonin Reuptake Inhibitors), Antiparkinson> Antipsychotics> Anxiolytics,> excess use of thyroxine, > NSAIDS and >long term use of Proton Pump Inhibitors may increase the risk of hip fractures.
7 Proton Pump Inhibitors The Proton Pump Inhibitors inhibit the production and intragastric secretion of hydrochloric acid which is believed to be an important mediator of calcium absorption in the small intestine. Recent studies have suggested that the use of PPI therapy is associated with hip fracture and other osteoporotic fractures.
8 Previously published studies Yu-Xiao Yang, James D. Lewis, Solomon Epstein. David C. Metz. Long-term Proton Pump inhibitor Therapy and Risk of Hip Fracture. JAMA, December 27, 2006-Vol 296, No. 24. Laura E. Targownik, Lisa M. Lix, Heather J. Prior, Stella Leung, William D. Leslie, Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ August 12; 179(4): P.Vestergaard, L. Rejnmark, L. Mosekilde. Proton Pump Inhibitors, Histamine D2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture. Calcified Tissue International August; 79:
9 Aims of the study: To determine the association between the prescribing of osteoporotic type medication (in particular bisphosphonates ) in patients receiving proton pump inhibitors. To determine if this association varied depending on dose and duration of PPI therapy.
10 Methodology: The cohort study used the Irish Health Services Executive (HSE) Primary Care Reimbursement Services (PCRS) pharmacy database. which contains prescription information for 1.2 million people in Ireland (30% of the population). It covers approximately 73% of all prescriptions issued and approximately 70% of the cost of medications. While the database is not linked to diagnosis, the use of bisphosphonates is specific for osteoporosis in the PCRS scheme as prescriptions for other conditions are reimbursed under other schemes within the Irish Healthcare system.
11 Adjusted odds ratios (OR and 95% CIs) were determined by logistic regression, adjusting for age, gender and other medications which potentially increase and decrease bone mineral density. Methodology cont d Data from 2003 was used as the run-in period where all patients who were prescribed a PPI or osteoporotic type medication were identified and excluded from the study. Those aged 55 years and over were included. Individuals were classified as new PPI users if they initiated PPI therapy after 2003, and those not receiving PPI therapy after 2003 were the controls. Subsequent prescribing of anti-osteoporotic therapy was considered from in both PPI user and control groups.
12 Study Cohort N= 896,919 Patients Excluded N= 27,185 N=869,734 All age grps N= 442,341 Over 55 yr agegrp PPI users N= 209,175 Non PPI users N=233,166 Subsequent osteo therapy N=42,589 (20.4%) Subsequent osteo Therapy N=31,779 (13.6%)
13 Table 1: Prescribing of anti-osteoporotic type meds subsequent to the prescribing of PPI therapy, results adjusted for Age and Gender Variable OR 95% CI P-Value PPI users vs Non-users 1.69 [ ] <.0001 Age band yrs vs 55-64yrs 70-74yrs vs 55-64yrs 75 + vs 55-64yrs [ ] [ ] [ ] Gender Female vs Male 4.31 [ ]
14 Table 2: Prescribing of anti-osteoporotic type meds subsequent to the prescribing of PPI therapy, results adjusted for Age and Gender and meds that increase or decrease BMD Variable OR 95% CI P-Value PPI users vs Non-users 1.28 [ ] <.0001 Age band yrs vs 55-64yrs 70-74yrs vs 55-64yrs 75 + vs 55-64yrs [ ] [ ] [ ] Gender Female vs Male 4.43 [ ]
15 Results: Duration of PPI therapy Duration of OR 95% CI P value therapy 0 3 months , months < months < months < months <.0001 > 24 months <.0001
16 Results: Dose response of PPI therapy Dose of PPI in ddds OR 95% CI 0-90 ddds >90 <=180ddds >180 <=360ddds >360 <=540ddds >540 <=720ddds >
17 Bisphosphonate prescribing after the prescribing of PPI therapy adjusted for age gender and other medications ORs 95% CI PPI users followed by Bisphos prscribing Agebands 65-69yrs vs 55-64yrs 70-74yrs vs 55-64yrs 75 + vs 55-64yrs Gender Females Vs Males
18 Main Findings The results of this study provide significant evidence of an association between the use of PPIs and subsequent prescribing of anti-osteoporotic agents in the general population. The response identified remains statistically significant even when adjusted for age and gender. When adjustments were made for other pharmacological confounders which have a known effect on bone mineral density, the OR decreased but still continued to be statistically significant.
Critique of evidence put forward by Servier suggesting an association between acid-suppressive medication and fracture risk. Dr Myfanwy Lloyd Jones
Critique of evidence put forward by Servier suggesting an association between acid-suppressive medication and fracture risk Dr Myfanwy Lloyd Jones February 2008 Background Proton pump inhibitors (PPIs)
More informationUse of proton pump inhibitors and risk of osteoporosisrelated
CMAJ Research Use of proton pump inhibitors and risk of osteoporosisrelated fractures Laura E. Targownik MD MSHS, Lisa M. Lix PhD, Colleen J. Metge PhD, Heather J. Prior MSc, Stella Leung MSc, William
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationMeasuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations
HRB PhD Scholar Division of Population Health Sciences RCSI Measuring and Evaluating Indicators of Appropriate Prescribing in Older Cost-Effective Proton Pump Populations Potential Strategies for more
More informationFamily Medicine Clinical Pharmacy Forum Vol. 3, Issue 1 (January/February 2007)
1 Family Medicine Clinical Pharmacy Forum Vol. 3, Issue 1 (January/February 2007) Family Medicine Clinical Pharmacy Forum is a brief bi-monthly publication from the Family Medicine clinical pharmacists
More informationThe Incidence of Hip Fracture Associated with Proton Pump Inhibitor (PPI) and/or H2 Receptor Antagonist (H2RA) Use in the Kentucky Medicaid Population
University of Kentucky UKnowledge MPA/MPP Capstone Projects Martin School of Public Policy and Administration 2011 The Incidence of Hip Fracture Associated with Proton Pump Inhibitor (PPI) and/or H2 Receptor
More informationOsteoporosis as a Focus for Practice Improvement
Osteoporosis as a Focus for Practice Improvement Karen E. Hansen, M.D. Assistant Professor of Medicine Rheumatology and Endocrine Sections University of Wisconsin Madison, WI Postmenopausal Osteoporosis
More informationHave COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?
et al. DOI:10.1111/j.1365-2125.2003.02012.x British Journal of Clinical Pharmacology Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Mary Teeling, Kathleen Bennett
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationFracture risk associated with drugs: a search for candidate drugs in the same way as for candidate genes
SPECIAL REPORT Fracture risk associated with drugs: a search for candidate drugs in the same way as for candidate genes Peter Vestergaard The Osteoporosis Clinic, Aarhus Amtssygehus, Tage Hansens Gade
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationProton Pump Inhibitors, Histamine H 2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture
Calcif Tissue Int (2006) 79:76 83 DOI: 10.1007/s00223-006-0021-7 Proton Pump Inhibitors, Histamine H 2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture P. Vestergaard, 1 L.
More informationCase Finding and Risk Assessment for Osteoporosis
Case Finding and Risk Assessment for Osteoporosis Patient may present as a fragility fracture or risk fracture Fragility fracture age 50 Clinical risk factors aged 50 Very strong clinical risk factors
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationPolypharmacy. A CPPE distance learning programme
A CPPE distance learning programme DLP 177 January 2016 Contents About CPPE distance learning programmes About this learning programme Glossary of key terms v vii ix Contents Section 1 The problem with
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationMeasuring Bone Mineral Density
Measuring Bone Mineral Density Osteoporosis Screening by Pharmacists 9/20/06 Don Downing Institute for Innovative Pharmacy Practice Today s Topics What is osteoporosis? What causes osteoporosis? Screening
More informationBONE HEALTH Dr. Tia Lillie. Exercise, Physical Activity and Osteoporosis
BONE HEALTH Dr. Tia Lillie Exercise, Physical Activity and Osteoporosis Food for thought... How old would you be if you didn t know how old you were? DEFINITION: Osteoporosis Osteoporosis (OP) is a disease
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationHow can we tell who will fracture? Beyond bone mineral density to the new world of fracture risk assessment
Copyright 2008 by How can we tell who will fracture? Beyond bone mineral density to the new world of fracture risk assessment Dr. Bone density testing: falling short of expectations More than 25 years
More informationParathyroid Hormone Analogs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.36 Subject: Parathyroid Hormone Analogs Page: 1 of 6 Last Review Date: September 15, 2017 Parathyroid
More informationOSTEOPOROSIS IN INDONESIA
OSTEOPOROSIS IN INDONESIA Hana Ratnawati Faculty of Medicine Maranatha Christian University Bandung - Indonesia 5th SBA Conference 2013 1 5th SBA Conference 2013 2 INTRODUCTION Indonesia is an archipelago
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationChallenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA
Challenging the Current Osteoporosis Guidelines Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Whom to screen Which test How to diagnose Whom to treat Benefits
More informationMisuse of Bisphosphonates. Dr Rukhsana Parvin Associate Professor Department of Medicine Enam Medical College & Hospital
Misuse of Bisphosphonates Dr Rukhsana Parvin Associate Professor Department of Medicine Enam Medical College & Hospital Introduction Bisphosphonates are chemically stable analogues of pyrophosphate compounds.
More informationNational Medicines Management Programme
National Medicines Management Programme Michael Barry 28 th November 2013 The Medicines Management Programme Multi-disciplinary Medicines Management Programme (MMP) headed by the National Medicines Information
More informationA Population-Based Study of the Effectiveness of Bisphosphonates at Reducing Hip Fractures among High Risk Women
A Population-Based Study of the Effectiveness of Bisphosphonates at Reducing Hip Fractures among High Risk Women APHA Conference Washington, DC November 2, 2011 Presenter Disclosures Kathy Schneider, PhD
More informationGuidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals
WA.DRUG EVALUATION PANEL Guidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals Introduction Osteoporotic fracture-related hospitalisations impose a substantial financial
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationMen and Osteoporosis So you think that it can t happen to you
Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School
More informationFalls and Fractures An Introduction. Sarah Leyland Senior Nurse and Helpline Manager National Osteoporosis Society
Falls and Fractures An Introduction Sarah Leyland Senior Nurse and Helpline Manager National Osteoporosis Society Definitions Osteoporosis is a systemic skeletal disease characterized by low bone mass
More informationObjectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING
Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationOsteoporosis Screening and Treatment in Type 2 Diabetes
Osteoporosis Screening and Treatment in Type 2 Diabetes Ann Schwartz, PhD! Dept. of Epidemiology and Biostatistics! University of California San Francisco! October 2011! Presenter Disclosure Information
More informationPrevention of Osteoporotic Hip Fracture
Prevention of Osteoporotic Hip Fracture Dr Law Sheung Wai 8th July 2007 Associate Consultant Spine team / Orthopedic Rehabilitation Department of Orthopedics and Traumatology NTE Cluster 1 Objectives Problems
More informationJuly 2012 CME (35 minutes) 7/12/2016
Financial Disclosures Epidemiology and Consequences of Fractures Advisory Board: Amgen Janssen Pharmaceuticals Inc. Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Osteoporotic
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationObjectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.
Objectives Discuss bone health and the consequences of osteoporosis on patients medical and disability status. Discuss the pathophysiology of osteoporosis and major risk factors. Assess the major diagnostic
More informationFragility Fracture Network - FFN
Fragility Fracture Network - FFN A Global Multidisciplinary Network to Improve Fragility Fracture Management and Prevention Ami Hommel RN, CNS, PhD, Associate Professor Lund University & Skane university
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationThe Glasgow UK Experiment: What a Working System Can Deliver
ASBMR Symposium Systems Approaches to Secondary Fracture Prevention: Doing Something that Actually Works The Glasgow UK Experiment: What a Working System Can Deliver Alastair R. McLellan MD, FRCP Western
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationAudit on follow-up of patients with primary Osteoporosis
Abstract Aim: To document the frequency of Dual-energy X- ray absorptiometry (DEXA) scanning and Rheumatology clinic follow-up visits of patients with primary osteoporosis, and compare these with recommended
More informationAssessment of the risk of osteoporotic fractures in Prof. J.J. Body, MD, PhD CHU Brugmann Univ. Libre de Bruxelles
Assessment of the risk of osteoporotic fractures in 2008 Prof. J.J. Body, MD, PhD CHU Brugmann Univ. Libre de Bruxelles Estimated lifetime fracture risk in 50-year-old white women and men Melton et al.;
More informationFragility Fracture Liaison Program Bridging the gap between the Publics and Private interface in management of osteoporosis after fragility fracture
Fragility Fracture Liaison Program Bridging the gap between the Publics and Private interface in management of osteoporosis after fragility fracture Law SW 1,2, Liu PL 1, Fung KY 1,2 1. Department of Orthopedic
More informationFragility Fractures and Secondary Fracture Prevention DeAnn Stowe, RN, MSN, ACNP-BC Cox Health- South Fracture Liaison Service
Fragility Fractures and Secondary Fracture Prevention DeAnn Stowe, RN, MSN, ACNP-BC Cox Health- South Fracture Liaison Service Objectives Define Fragility Fractures and discuss importance of identification
More informationOsteoporosis 2017 Breaking News. Julie L. Carkin, MD The Seattle Arthritis Clinic
Osteoporosis 2017 Breaking News Julie L. Carkin, MD The Seattle Arthritis Clinic 1 Yes, Hopefully & No Anabolic Teriparatide Abaloparatide Romosozumab blosozumab Anti-catabolic Bisphosphonates Denosumab
More informationPFIZER INC. What is the difference in incidence of fracture in women who ever or never used DMPA for contraception?
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationMeta-analysis: analysis:
1 Diabetes and TZDs: Risk Factors for Fracture Ann Schwartz, PhD Dept. of Epidemiology and Biostatistics University of California San Francisco July 2010 Osteoporosis CME Presenter Disclosure Information
More informationTalking to patients with osteoporosis about initiating therapy
Talking to patients with osteoporosis about initiating therapy Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for
More informationEpidemiology and Consequences of Fractures
Epidemiology and Consequences of Fractures Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Financial Disclosures Advisory Board: Amgen Research Support: Hologic 24July12 1 Outline
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationPractical Guide to Safety of PPIs What to Tell Your Patient. Proton Pump Inhibitors
Practical Guide to Safety of PPIs What to Tell Your Patient Joel E Richter, MD, FACP, MACG Professor and Director Division of Digestive Diseases and Nutrition Joy Culverhouse Center for Esophageal Diseases
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationOsteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon
Osteoporosis in Men Wendy Rosenthal PharmD This program has been brought to you by PharmCon Osteoporosis in Men Speaker: Dr. Wendy Rosenthal, President of MedOutcomes, will be the presenter for this webcast.
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationOsteoporosis/Fracture Prevention Clinical Practice Guidelines
NATIONAL CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinical Practice Guidelines Reviewed/Approved by the National Guideline Directors September 2017 Next Review/Approval: September
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationSilent Killer: Osteoporosis
Special Dedication to the Old Females Silent Killer: Osteoporosis David Goltzman, Discoveries, Drugs and Skeletal Disorders Nature, Volume 1, October 2002, pp784-796 BII Journal Club Wang Zhengyuan 5:00-5:30pm
More informationLONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS. Jihane Naous, M.D.
LONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS Jihane Naous, M.D. Objectives Identify the conditions supported by AGA/ACG guidelines necessitating long-term use of daily PPIs, Recognize which
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationUse of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia
Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia Aine Leen, Kieran Walsh, David O Sullivan, Denis O Mahony, Stephen Byrne, Margaret Bermingham Pharmaceutical Care Research Group,
More informationNew York State County Comparison of Fall-related Hip Fractures of Older Adults and Number of Dual-X-ray Absorptiometry Machines
New York State County Comparison of Fall-related Hip Fractures of Older Adults and Number of Dual-X-ray Absorptiometry Machines Michael Bauer New York State Department of Health Bureau of Occupational
More informationMeasuring drug exposure: rationale and methods
Measuring drug exposure: rationale and methods Hubert G. Leufkens Declaration of interests Chairman of the Dutch Medicines Evaluation Board (MEB), since mid 2007. Professor of Pharmacoepidemiology, Utrecht
More information1. UK List Price of Zoledronic acid (Zoledronate) 5 mg (Aclasta )
Novartis Pharmaceuticals UK Ltd Frimley Business Park Frimley Camberley Surrey GU16 7SR Dr C M Longson Director, Centre for Health Technology Evaluation National Institute for Health and Clinical Excellence
More informationTREATMENT OF OSTEOPOROSIS
TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationMake your. first break. your last.
www.iofbonehealth.org Make your first break your last WHAT IS OSTEOPOROSIS? Osteoporosis is a disease in which bones become more fragile and weak, leading to an increased risk of fractures (broken bones).
More informationDENOSUMAB (PROLIA & XGEVA )
DENOSUMAB (PROLIA & XGEVA ) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 306.3 T2 Effective Date: July 2, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationMedical Director Update
Medical Director Update Articles: Bone Density Test Can Predict Fractures Over Twenty-Five Years Community Awareness Bone Density Testing Program: 18 Months Experience More Attention Should Be Paid To
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationDartmouth General Hospital Fracture Liaison Service. Carla Purcell BScN, RN, CMSN(C) Fracture Navigator
Dartmouth General Hospital Fracture Liaison Service Carla Purcell BScN, RN, CMSN(C) Fracture Navigator Acknowledgments Dr. Diane Theriault Heather Francis DGH Ortho Clinics Points to Cover Osteoporotic
More informationCOPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017
COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former
More informationUse of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
Osteoporos Int (2011) 22:903 910 DOI 10.1007/s00198-010-1337-8 ORIGINAL ARTICLE Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study S. Pouwels & A. Lalmohamed
More informationa Department of Health Statistics and b Information Center, Second Military
794 Original article Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis Xiaofei Ye a, *,HongLiu b, *, Cheng Wu a, *, Yingyi Qin a, Jiajie Zang a, Qingbin Gao
More informationHelpful information about bone health & osteoporosis Patient Resource
Helpful information about bone health & osteoporosis Patient Resource Every year In the United States, 2.5 million fractures occur due to osteoporosis. Out of these, 330,000 are hip fractures, and half
More informationdeterminants of persistence with bisphosphonate A Study in Women with Postmenopausal Osteoporosis
Clinical Therapeutics/Volume 28, Number 2, 2006 Determinants of Persistence with Bisphosphonates: A Study in Women with Postmenopausal Osteoporosis FernieJ.A. Penning-van Beest, PhD1; Wim G. Goettsch,
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationLong-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture JAMA. 2006;296:
ORIGINAL CONTRIBUTION Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture Yu-Xiao Yang, MD, MSCE James D. Lewis, MD, MSCE Solomon Epstein, MD David C. Metz, MD Context Proton pump inhibitors
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationIssue date: October Review date: July 2010
Issue date: October 2008 Review date: July 2010 Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal
More informationNIH Public Access Author Manuscript Am J Med. Author manuscript; available in PMC 2012 June 1.
NIH Public Access Author Manuscript Published in final edited form as: Am J Med. 2011 June ; 124(6): 519 526. doi:10.1016/j.amjmed.2011.01.007. Proton pump inhibitors and risk of fractures: a meta-analysis
More informationAntidepressant use and risk of adverse outcomes in people aged years: cohort study using a primary care database
Coupland et al. BMC Medicine (2018) 16:36 https://doi.org/10.1186/s12916-018-1022-x RESEARCH ARTICLE Open Access Antidepressant use and risk of adverse outcomes in people aged 20 64 years: cohort study
More informationPerplexed by PPI s Should I be Worried? James R Gray Gastroenterology Vancouver
Perplexed by PPI s Should I be Worried? James R Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationSummary of the risk management plan by product
Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks
More information